096530.KQ
Seegene, Inc.
KOE · Healthcare · Medical - Specialties · KR
KRW 31,550.00
−1.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 509.3B | 474.2B | 414.3B | 367.4B | 853.6B |
| Cost of Revenue | 198.1B | 203.3B | 175.6B | 187.3B | 387.4B |
| Gross Profit | 311.2B | 271.0B | 238.6B | 180.1B | 466.1B |
| Operating Expenses | |||||
| R&D Expense | 44.5B | 66.3B | 69.4B | 72.7B | 94.4B |
| SG&A Expense | 61.0B | 80.9B | 69.4B | 138.1B | 190.8B |
| General & Admin Expense | 30.3B | 38.6B | 37.8B | 35.1B | 44.2B |
| Selling & Marketing Expense | 30.7B | 42.3B | 31.7B | 30.4B | 44.6B |
| Other Expenses | 157.7B | 89.1B | 116.3B | (719.8M) | (19.9M) |
| Total Operating Expenses | 245.5B | 236.3B | 255.1B | 210.1B | 285.2B |
| Cost and Expenses | 443.7B | 439.7B | 430.7B | 397.4B | 672.6B |
| Operating Income (EBIT) | 65.6B | 34.5B | (16.5B) | (30.0B) | 196.5B |
| Non-Operating | |||||
| Interest Income | 13.5B | 13.7B | 18.6B | 17.5B | 6.8B |
| Interest Expense | 4.0B | 4.5B | 5.9B | 6.2B | 5.4B |
| Net Interest Income | 9.5B | 9.2B | 12.7B | 11.3B | 1.3B |
| Other Non-Op Income/Expense | 42.0B | 21.9B | 7.1B | 28.6B | 29.1B |
| Non-Operating Income (excl Interest) | (19.0B) | — | (12.9B) | (31.6B) | (41.2B) |
| EBT (Pre-Tax Income) | 107.5B | 56.4B | (9.4B) | (1.4B) | 225.6B |
| Income Tax Expense | 27.2B | 8.0B | 10.8B | (2.1B) | 43.1B |
| Bottom Line | |||||
| Net Income | 80.2B | 48.4B | (20.3B) | 669.0M | 182.1B |
| Earnings from Cont. Ops | 80.3B | 48.4B | (20.3B) | 733.2M | 182.4B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 80.2B | 48.4B | (20.3B) | 669.0M | 182.1B |
| Per Share | |||||
| Basic EPS | ₩1,667 | ₩1,047 | (₩439) | ₩14 | ₩3,586 |
| Diluted EPS | ₩1,664 | ₩1,047 | (₩439) | ₩14 | ₩3,586 |
| Revenue Per Share | ₩9,745 | ₩9,080 | ₩8,975 | ₩7,792 | ₩16,806 |
| Shares | |||||
| Basic Shares Outstanding | 52.3M | 52.2M | 46.2M | 47.1M | 50.8M |
| Diluted Shares Outstanding | 52.3M | 52.2M | 46.2M | 47.1M | 50.8M |
| Profitability Metrics | |||||
| EBITDA | 143.1B | 104.6B | 67.5B | 67.3B | 280.1B |
| D&A | 67.3B | 69.8B | 71.2B | 65.7B | 57.9B |
| EBIT | 75.8B | 34.5B | (3.6B) | 1.6B | 222.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026